Our 2025 Human Health cohort

Meet the innovators that were selected for our cohort tackling key human health challenges.

Through our tailored programme of venture mentoring, masterclasses, investment support, and more, we will work with them to accelerate their technologies and realise their impact for better treatment and diagnosis to improve and save lives.

Zonova

Antimicrobial technology embedded in medical devices to prevent infection.

Zonova’s patented antimicrobial technology is embedded into medical devices, such as IV lines and catheters, at the manufacturing stage. This creates a protective surface that continuously kills a broad spectrum of pathogens, including drug-resistant strains like MRSA. This aims to prevent hospital-acquired infections, reduce antibiotic reliance, and lower healthcare costs.

Read more

Explore the community

Find out more about who we support through our accelerator programme.

Advanced Nanoparticles

Nanocomposite fluorophore which eliminates autofluorescence interference to image fine details.

Autofluorescence interference of intrinsic biomolecules hinders resolution of fine details in bioimaging at the cellular level. We have developed a nanocomposite fluorophore which displays persistent room-temperature phosphorescence which fluoresces longer than the interference and allowing fine-detail distinctions at the cellular level and advancing disease understanding and treatments, for example.

Explore the community

Find out more about who we support through our accelerator programme.

New Path Molecular

Building biologics better with synthetic chemistry.

We have developed a chemistry platform enabling medicinal chemistry on proteins. Inspired by natural proteins, we remake them from the amino acids up, optimising their properties, developing therapies for hard-to-treat diseases. Our lead project is a tumour agnostic drug conjugate for high-unmet medical need cancers including colon and pancreas.

Read more

Explore the community

Find out more about who we support through our accelerator programme.

Molecular Titans

Materials providing rapid information on the identity of infectious microbes.

We are developing rapid point of care diagnostics for infectious diseases that do not require laboratory facilities. The technology is based on unique smart nano-polymer materials and state-the-art macromolecular physics concepts.

Read more

Explore the community

Find out more about who we support through our accelerator programme.

ModelMole

Creative thinking in therapeutics with easy simulation and validation

ModelMole accelerates drug discovery with an integrated AI platform, automating compound design and optimisation. Unlike niche competitors, our broader solution combines machine learning and computational chemistry to address diverse therapeutic areas at significantly reduced costs. We’ve proven success with European biotech firms, driving faster, efficient drug and peptide candidate development.

Read more

Explore the community

Find out more about who we support through our accelerator programme.

Microsol

Accerelated formulation development for inhaled therapies

We're rethinking how inhaled drugs are formulated. At Microsol, we combine precise single-particle measurements with predictive simulations to design better formulations, faster. That means earlier decisions, less material, and fewer failures. It’s a smarter, de-risked path to delivering complex therapies, especially biologics, into the lungs where they need to work.

Read more

Explore the community

Find out more about who we support through our accelerator programme.

ConsoneAI

Reducing animal testing with AI-driven cross-species toxicity predictions

DioScor is an AI-powered decision support platform that predicts toxicity and side effects across multiple animals and humans. Enabling early comparison of compound safety profiles, reducing reliance on animal testing, lowers development risks, and accelerates safer drug/molecule discovery decisions from go/no-go to molecule redesign before any testing.

Read more

Explore the community

Find out more about who we support through our accelerator programme.

BlaiseAI

AI-first platform accelerating medicinal chemistry innovation and drug discovery.

Blaise AI is a medicinal chemistry-first LLM platform that empowers drug developers with intelligent design, automated scoring, and knowledge recall. By integrating project data, running analyses offline, and simulating the output of an expert team, Blaise AI accelerates discovery while freeing scientists to focus on creativity and critical decision-making.

Read more

Explore the community

Find out more about who we support through our accelerator programme.

Explore the Change Makers community

Want to see more deep tech chemistry ideas? See our venture gallery to explore the companies and technologies that are further along our venture support programme.

See our ventures